Acessibilidade / Reportar erro
Revista Brasileira de Hematologia e Hemoterapia, Volume: 35, Número: 6, Publicado: 2013
  • The last issue of the year, a retrospective and a new perspective for the Revista Brasileira de Hematologia e Hemoterapia Editorial

    Ruiz, Milton Artur
  • Relationship between splenomegaly and hematologic findings in patients with hepatosplenic schistosomiasis Scientific Comments

    Kaiser Junior, Roberto Luiz
  • Chronic myeloid leukemia: an overview of the determinants of effectiveness and therapeutic response in the first decade of treatment with imatinib mesylate in a Brazilian hospital Scientific Comments

    Conchon, Monika
  • Blood discard rate and the prevalence of infectious and contagious diseases in blood donors from provincial towns of the state of Paraná, Brazil Scientific Comments

    Venturini, Danielle
  • Dombrock genotyping in Brazilian blood donors reveals different regional frequencies of the HY allele Scientific Comments

    Mattos, Luiz Carlos de
  • Oxidative stress and antioxidant status in beta-thalassemia heterozygotes Scientific Comments

    Shekhar, Hossain Uddin
  • Study of possible clinical and laboratory predictors of alloimmunization against red blood cell antigens in cancer patients Scientific Comments

    Castilho, Lilian
  • Chronic myeloid leukemia: an overview of the determinants of effectiveness and therapeutic response in the first decade of treatment with imatinib mesylate in a Brazilian hospital Original Articles

    Cid, Danielle Maria Camelo; Magalhães, Silvia Maria Meira; Quixadá, Acy Telles de Souza; Honório, Rita Paiva Pereira; Costa, Paola Franssinetti Torres Ferreira; Reis, Samuel Roosevelt Campos dos; Carvalho, Selda Maria de Aguiar; Cid, David Antonio Camelo; Sucupira, Rafael Moura e; Oliveira, Mariana Fátima Cabral de

    Resumo em Inglês:

    Background: In the last decade, there has been a revolution in chronic myeloid leukemia treatment with the introduction of tyrosine kinase inhibitors with imatinib mesylate becoming the frontline therapy. Objective: To evaluate the therapeutic efficacy of imatinib mesylate in treating chronic myeloid leukemia patients and to identify factors related to therapeutic efficacy. Methods: This retrospective study was based on information obtained from patients'records in the Hematology Service of Hospital Universitário Walter Cantídio of the Universidade Federal do Ceará (HUWC / UFC). All patients diagnosed with chronic myeloid leukemia that took imatinib mesylate for a minimum of 12 months in the period from January 2001 to January 2011 were included. From a population of 160 patients, 100 were eligible for analysis. Results: The study population consisted of 100 patients who were mostly male (51%) with ages rangingbetween 21 and 40 years (42%), from the countryside (59%), in the chronic phase (95%), with high-riskprognostic factors (40%); the prognosis of high risk was not associated with complete hematologic responseor complete cytogenetic response, but correlated to complete molecular response or major molecularresponse. Reticulin condensation was associated with complete hematologic response and completecytogenetic response. It was found that 53% of patients had greater than 90% adherence to treatment. Thehigh adherence was correlated to attaining complete cytogenetic response in less than 12 months. Moreover,20% of patients had good response. Conclusion: Significant changes are indispensable in the monitoring of patients with chronic myeloid leukemia. Thus, the multidisciplinary team is important as it provides access to the full treatment and not just to medications.
  • Blood discard rate and the prevalence of infectious and contagious diseases in blood donors from provincial towns of the state of Paraná, Brazil Original Articles

    Borelli, Sueli Donizete; Mazzola, Jocimara Costa; Matta, Alessandra Cristina Gobbi; Takemoto, Angélica Yukari; Bértoli, Marta

    Resumo em Inglês:

    Background: So that an improvement in the selection of donors can be achieved and the risk to the recipient of transfused blood can be reduced, prospective donors are submitted to clinical and serological screening. Objective: This study investigated the blood discard rate and the rate of infectious and contagious diseases in blood donors from provincial towns of the state of Paraná, Brazil. Methods: This study was an exploratory cross-sectional descriptive investigation with a quantitative approach of donations between January and December 2011. Results: In the study period the Regional Blood center in Maringá, Brazil received 8337 blood donations from people living in the city and neighboring towns. However, 278 (3.33%) donations were discarded during serological screening owing to one or more positive serological markers. A total of 46.4% of the discarded blood units were confirmed positive by serology with anti-HBc being the most common (66.7%), followed by syphilis (22.5%), HBsAg (4.7%), anti-hepatitis C virus (3.1%), human immunodeficiency virus (1.5%) and Chagas' disease (1.5%). The rate of infectious-contagious diseases that can be transmitted by blood transfusions was 1.55% (129/8337) of the donor population with a frequency of 1.03% for anti-HBc and 0.35% for syphilis. Conclusion: This study demonstrates a high prevalence of the anti-HBc marker in prospective blood donors from provincial towns in the state of Paraná, Brazil.
  • Dombrock genotyping in Brazilian blood donors reveals different regional frequencies of the HY allele Original Articles

    Piassi, Fabiana Chagas Camargos; Santos, Silvana Maria Eloi; Castilho, Lilian Maria de; Baleotti Júnior, Wilson; Suzuki, Rodrigo Buzinaro; Cunha, Débora Moura da

    Resumo em Inglês:

    Background: Dombrock blood group system genotyping has revealed various rearrangements of the Dombrock gene and identified new variant alleles in Brazil (i.e., DO*A-SH, DO*A-WL and DO*B-WL). Because of the high heterogeneity of the Brazilian population, interregional differences are expected during the investigation of Dombrock genotypes. Objective: The present study aims to determine the frequencies of Dombrock genotypes in blood donors from Minas Gerais and compare the frequencies of the HY and JO alleles to those of another population in Brazil. Methods: The frequencies of the DO alleles in Minas Gerais, a southeastern state of Brazil, were determined from the genotyping of 270 blood donors. Genotyping involved polymerase chain reaction and restriction fragment length polymorphism analysis to identify the 323G>T, 350C>T, 793A>G, and 898C>G mutations, which are related to the HY, JO, DO*A/DO*B, and DO*A-WL/DO*B-WL alleles, respectively. Moreover, the frequencies of rare HY and JO alleles were statistically compared using the chi-square test with data from another Brazilian region. Results: The HY allele frequency in Minas Gerais (2.4%) was almost twice that of the JO allele (1.5%). The frequency of the HY allele was significantly higher (p-value = 0.001) than that in another Brazilian population and includes a rare homozygous donor with the Hy- phenotype. In addition, the DO*A-WL and DO*B-WL alleles, which were first identified in Brazil, were found in the state of Minas Gerais. Conclusions: The data confirm that the frequencies of DO alleles differ between regions in Brazil. The population of Minas Gerais could be targeted in a screening strategy to identify the Hy- phenotype in order to develop a rare blood bank.
  • Validation of the Sysmex sp-1000i automated slide preparer-stainer in a clinical laboratory Original Articles

    Bitencourt, Eberson Damião dos Santos de; Voegeli, Carlos Franco; Onzi, Gabriela dos Santos; Boscato, Sara Cardoso; Ghem, Carine; Munhoz, Terezinha

    Resumo em Inglês:

    Background: The speed and quality of information have become essential items in the release of laboratory reports. The Sysmex®SP1000-I device has been developed to prepare and stain smear slides. However, for a device to be cleared for use in the laboratory routine it must pass through a validation process. Objective: To evaluate the performance and reliability of the Sysmex® SP-1000i slide preparer-stainer incorporated into the routine of a hospital laboratory in Porto Alegre. Methods: Peripheral blood samples of patients attending the laboratory for ambulatory exams with leukocyte counts between 7000/°L and 12,000/°L were evaluated, independent of gender and age. Two slides were prepared for each sample using the Sysmex® SP-1000i equipment; one of the slides was used to perform quality control tests using the CellaVision® DM96 device, and the other slide was used to compare pre-classification by the same device and the classification performed by a pharmacist-biochemist. Results: The results of all the slides used as controls were acceptable according to the quality control test as established by the manufacturer of the device. In the comparison between the automated pre-classification and the classification made by the professional, there was an acceptable variation in the differential counts of leukocytes for 90% of the analyzed slides. Pearson correlation coefficient showed a strong correlation for band neutrophils (r = 0.802; p-value < 0.001), segmented neutrophils (r = 0.963; p-value < 0.001), eosinophils (r = 0.958; p-value < 0.001), lymphocytes (r = 0.985; p-value < 0.001) and atypical lymphocytes (r = 0.866; p-value < 0.001) using both methods. The red blood cell analysis was adequate for all slides analyzed by the equipment and by the professional. Conclusion: The new Sysmex®SP1000-i methodology was found to be reliable, fast and safe for the routines of medium and large laboratories, improving the quality of microscopic analysis in complete blood counts.
  • Oxidative stress and antioxidant status in beta-thalassemia heterozygotes Original Articles

    Ondei, Luciana de Souza; Estevão, Isabeth da Fonseca; Rocha, Marina Ibelli Pereira; Percário, Sandro; Souza, Dorotéia Rossi Silva; Pinhel, Marcela Augusta de Souza; Bonini-Domingos, Claudia Regina

    Resumo em Inglês:

    Background: Several studies have evaluated the oxidant and antioxidant status of thalassemia patients but most focused mainly on the severe and intermediate states of the disease. Moreover, the oxidative status has not been evaluated for the different beta-thalassemia mutations. Objective: To evaluate lipid peroxidation and Trolox equivalent antioxidant capacity in relation to serum iron and ferritin in beta thalassemia resulting from two different mutations (CD39 and IVS-I-110) compared to individuals without beta-thalassemia. Methods: One hundred and thirty subjects were studied, including 49 who were heterozygous for beta-thalassemia and 81 controls. Blood samples were subjected to screening tests for hemoglobin. Allele-specific polymerase chain reaction was used to confirm mutations for beta-thalassemia, an analysis of thiobarbituric acid reactive species was used to determine lipid peroxidation, and Trolox equivalent antioxidant capacity evaluations were performed. The heterozygous beta-thalassemia group was also evaluated for serum iron and ferritin status. Results: Thiobarbituric acid reactive species (486.24 ± 119.64 ng/mL) and Trolox equivalent antioxidant capacity values (2.23 ± 0.11 mM/L) were higher in beta-thalassemia heterozygotes compared to controls (260.86 ± 92.40 ng/mL and 2.12 ± 0.10 mM/L, respectively; p-value < 0.01). Increased thiobarbituric acid reactive species values were observed in subjects with the CD39 mutation compared with those with the IVS-I-110 mutation (529.94 ± 115.60 ng/mL and 453.39 ± 121.10 ng/mL, respectively; p-value = 0.04). However, average Trolox equivalent antioxidant capacity values were similar for both mutations (2.20 ± 0.08 mM/L and 2.23 ± 0.12 mM/L, respectively; p-value = 0.39). There was no influence of serum iron and ferritin levels on thiobarbituric acid reactive species and Trolox equivalent antioxidant capacity values. Conclusion: This study shows an increase of oxidative stress and antioxidant capacity in beta-thalassemia heterozygotes, mainly in carriers of the CD39 mutation.
  • Study of possible clinical and laboratory predictors of alloimmunization against red blood cell antigens in cancer patients Original Articles

    Dinardo, Carla Luana; Ito, Gláucia Munemasa; Sampaio, Luciana Ribeiro; Mendrone Júnior, Alfredo

    Resumo em Inglês:

    Background: The inflammatory background of patients influences the process of alloimmunization against red blood cell antigens. Proof of this statement to clinical practice is still lacking. Objective: The aim of this study was to verify whether factors related to disease severity and inflammatory status of cancer patients can predict alloimmunization. Methods: This was a case-control study in which alloimmunized oncologic patients treated between 2009 and 2012 were compared with a non-alloimmunized control group regarding the severity of the disease (metastasis/performance status/body mass index) and C-reactive protein levels. Results: The groups did not differ significantly in terms of C-reactive protein, Eastern Cooperative Oncology Group (ECOG)/Karnofsky performance status, presence of metastasis and body mass index. Conclusion: It is not possible to predict alloimmunization in cancer patients based on severity of illness and inflammatory markers. Strategies of screening patients by phenotyping blood based on these criteria are not justified.
  • Guidelines on the treatment of primary immune thrombocytopenia in children and adolescents: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2012 Special Article

    Loggetto, Sandra Regina; Braga, Josefina Aparecida Pellegrini; Veríssimo, Mônica Pinheiro de Almeida; Bernardo, Wanderley Marques; Medeiros, Leticia; Hoepers, Andrea Thives de Carvalho
  • Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion Special Article

    Veríssimo, Monica Pinheiro de Almeida; Loggetto, Sandra Regina; Fabron Junior, Antonio; Baldanzi, Giorgio Roberto; Hamerschlak, Nelson; Fernandes, Juliano Lara; Araujo, Aderson da Silva; Lobo, Clarisse Lopes de Castro; Fertrin, Kleber Yotsumoto; Berdoukas, Vasilios Antonios; Galanello, Renzo

    Resumo em Inglês:

    In the absence of an iron chelating agent, patients with beta-thalassemia on regular transfusions present complications of transfusion-related iron overload. Without iron chelation therapy, heart disease is the major cause of death; however, hepatic and endocrine complications also occur. Currently there are three iron chelating agents available for continuous use in patients with thalassemia on regular transfusions (desferrioxamine, deferiprone, and deferasirox) providing good results in reducing cardiac, hepatic and endocrine toxicity. These practice guidelines, prepared by the Scientific Committee of Associação Brasileira de Thalassemia (ABRASTA), presents a review of the literature regarding iron overload assessment (by imaging and laboratory exams) and the role of T2* magnetic resonance imaging (MRI) to control iron overload and iron chelation therapy, with evidence-based recommendations for each clinical situation. Based on this review, the authors propose an iron chelation protocol for patients with thalassemia under regular transfusions.
  • Late cytomegalovirus infection after hematopoietic stem cell transplantation: case reports Case Report

    Pinheiro, Sâmara Grapiuna; Matos, Sócrates Bezerra de; Botura, Mônica Borges; Meyer, Roberto; Lima, Fernanda Washington de Mendonça

    Resumo em Inglês:

    Cytomegalovirus is related to high rates of morbidity and mortality after hematopoietic stem cell transplantation. This report highlights the importance of adequate monitoring and management of this infection. We report on two cases of patients with late subclinical cytomegalovirus infection. These patients were monitored for antigenemia by indirect immunofluorescence assay. Active cytomegalovirus infection is most common in the first three months after transplantation however the cases reported herein show the importance of monitoring for active infection after Day +100 post-transplantation. Early detection of active infection enables quick preemptive therapy. In conclusion, we emphasize that patients with risk factors for developing severe or late cytomegalovirus disease should be monitored for more than 100 post-transplant days as late active infection is a reality.
  • Myelodysplastic syndrome versus idiopathic cytopenia of undetermined significance: the role of morphology in distinguishing between these entities Images

    Santos, Talyta Ellen de Jesus dos; Gonçalves, Romélia Pinheiro; Duarte, Fernando Barroso
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular R. Dr. Diogo de Faria, 775 cj 114, 04037-002 São Paulo/SP/Brasil, Tel. (55 11) 2369-7767/2338-6764 - São Paulo - SP - Brazil